Biosimilar Orphan Drugs For Rare Diseases: A Comparative Review Of Regulatory Frameworks And Market Dynamics In The US And EU

A Medicinal product designated as an Orphan Drug or Biosimilar Orphan Drug is specifically developed to treat rare conditions known as “Orphan Diseases.” These medicines are often not pursued by the pharmaceutical industry due to economic factors, despite addressing significant public health needs. The rising costs associated with drug development, along with stringent regulatory compliance and limited patient populations, create a disincentive for pharmaceutical innovators. Approximately 80% of rare diseases are genetic; others stem from infections, allergies, or degenerative and proliferative causes. This prevalence of rare diseases presents a crucial public health challenge, as current treatment options remain scarce. Consequently, the increasing demand for public health protection exacerbates the financial burden faced by patients afflicted with these conditions.[1]

Scientific developments have given researchers new ways to study rare diseases, which are usually more complicated than common illnesses. Given that there are over 7,000 different varieties of these rare diseases, and that number is constantly increasing due to new discoveries, they cannot all be considered rare. Approximately 250 new cases are thought to occur globally each year, but only 200 to 300 orphan illnesses have effective therapies. Interestingly, bacterial or viral infections, environmental factors, or unknown causes may be responsible for the remaining 80% of these uncommon disorders. Additionally, orphan diseases exhibit traits including chronicity, progressive decline, and the possibility of impairment or fatal consequences. Despite their high complexity and low prevalence rates, several of these illnesses have effective treatment options.[1]

Orphan Drug

An Orphan Drug is used to treat, prevent, or diagnose an orphan disease. An orphan disease is a rare disease or condition that affects the patient in many countries. A medicinal product designed as an orphan drug that one that is developed specifically to treat a rare medical condition referred to as an orphan disease”. Due to special orphan drug regulations in both the US and EU, the number of approved orphan drugs is steadily increasing in the world.[2]

Biosimilars

 A Biosimilar drug is a medicine that is very similar in structure and function to a biological medicine. A biological drug is a medicine made from living organisms such as yeast, bacteria, animal cells, etc.[3]

 Biosimilar Orphan Drug is a biological that is almost an identical copy of an original product that is manufactured by a different company in the world. Biosimilars orphan drugs are officially approved new versions of original "innovator" products and can be manufactured when the original product's patent expires.[4] Biosimilar orphan medications are biological pharmaceuticals whose active components are produced by living organisms through controlled gene expression or recombinant DNA technology.[5] The biosimilars market is projected to reach a value of US$19.4 billion by 2014, with a compound annual growth rate (CAGR) of 89.1% between 2009 and 2014. Biosimilars are a safe and efficient way to treat a variety of disorders, including cancer, kidney diseases, arthritis, and chronic skin and intestinal conditions.[6] Biosimilar medications increase access to possibly less expensive life-saving medications. A medication that shares structural and functional similarities with a biological therapy is called a biosimilar. Living things like bacteria, yeast, or animal cells are used to make biological medicine. Products made from blood and plasma, pure non-recombinant proteins from natural sources, monoclonal antibodies, recombinant proteins, cell-cultured cells and tissues, vaccinations, and derived protein products are examples of biosimilars. Biosimilar medicines enhance access to essential treatments at potentially reduced prices. A biosimilar is a drug that closely resembles a biological medicine in both structure and function, which is produced by living organisms like yeast, bacteria, or animal cells. Biosimilars can include various products such as those derived from blood and plasma, non-recombinant proteins, monoclonal antibodies, recombinant proteins, cultured cells and tissues, vaccines, and derived protein products. They are developed for conditions including rheumatoid arthritis, non-Hodgkin's lymphoma, diabetes mellitus, and macular degeneration. Biosimilars demonstrate safety and efficacy comparable to original drugs and are considered interchangeable, meaning they can replace the original product while achieving the same clinical effect in patients as shown in specific clinical trials.[5]

United States biosimilar orphan drug conditions

The US Biosimilar Orphan Act of 2003 facilitated the creation of three biosimilars for rare diseases: somatropin (human growth hormone), filgrastim (human granulocyte colony-stimulating factor), and epoetin, among others. As of now, the FDA has approved 39 biosimilars for various reference biologics, with 23 currently on the market. Additionally, 10 biosimilars are anticipated to launch soon, particularly for adalimumab. Approximately 7,000 rare diseases impact 25 to 30 million Americans, with 95% lacking effective treatments. The previous year marked a record with 40 specialty drug approvals from the FDA, representing 75% of all drug approvals, and 222 novel medications have been sanctioned this year, with 16 more expected by the end of 2023. [7]

European Union Biosimilar Orphan Drug Conditions.

The European Medicine Agency (EMA) defines “A biosimilar as a biological medicinal product containing a version of the active substance of an already authorized original biological orphan product in the European Economic Area (EEA).” Now the European medicines agency (EMA) is starting to develop advanced pharmaceutical technology for the production or manufacture of biosimilar medicine for orphan diseases in the EU. They are the therapeutic equivalents of originator drugs and offer the opportunity to reduce the high cost of biological treatment in EMA.[8] In many countries, their respective country governments and regulators should implement incentive structures for the development of orphan biosimilars around the world. In addition, the government has paved the way for a clear trend toward the development of orphan drugs. However, this positive effect has serious implications for access to affordable biosimilar medicines for rare diseases. [29] In Europe, all new biosimilar approvals for biologics and small molecule orphan drugs are subject to an enhanced mandatory pharmacovigilance surveillance study and are marked with an inverted black triangle in the prescribing information. This requirement also applies to biosimilars and provides a safe comfort zone. EU pharmacovigilance has not identified any particular safety concerns or new safety signals for any of the biosimilars authorized in the EU since 2006.[9]

Table No.02: Comparison for USA and EU

Sr.No	Parameters	USA	EU
1	Legal framework	BPCI Act [10]	Regulation 141/2000 [11]
2.	Exclusivity	12 years  [12]	10 years [11]
3.	Interchangeability	FDA designated [10]	Member-state policy [10]

 

 

Fig no.01: Overview of biosimilar [13]

 

 

 

 

 

 

                       

 

Fig No .02: biosimilar approval pathway in USA[14]

 

 

Fig No.03: Biosimilar approval pathway in EU[15]

CONCLUSION

The orphan drug and biosimilar programs for rare diseases have faced challenges in achieving success due to inadequate incentives. The Orphan Drug Act (ODA) has played a role in advancing orphan products. For global benefits, countries must evaluate their R&D investments, returns, tax incentives, and regulatory frameworks. While the US and Europe are leaders in biosimilar development, regulatory approaches vary. Recent efforts by the US, EU, and India focus on harmonizing biosimilar regulations to enhance affordability. Orphan drugs and biosimilar drugs are vital for treating rare genetic diseases and are projected to grow, benefiting public health and offering hope for future treatments.

REFERENCES

1. National Organization for Rare Disorders (NORD) https://rarediseases. org/. 2017.
2. https://en.wikipedia.org/wiki/Orphan_drug.
3. Kalyani Y, Shyamala. A COMPREHENSIVE REVIEW ON BIOSIMILARS. World Journal of Pharmaceutical Research [Internet]. 2019;8. Available from: www.wjpr.net
4. Medicines Agency E. Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) [Internet]. 2012. Available from: www.ema.europa.
5. English only final expert committee on biological standardization geneva guidelines on evaluation of similar biotherapeutic products (sbps).
6. Golshani S, Faramarzi MA. Expected impact of biosimilars on the pharmaceutical companies. Vol. 46, Iranian Journal of Medical Sciences. Shriaz University of Medical Sciences; 2021. p. 399–401.
7. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information.
8. Schiestl M, Zabransky M, Sörgel F. Ten years of biosimilars in Europe: Development and evolution of the regulatory pathways. Drug Design, Development and Therapy. 2017 May 16;11:1509–15.
9. Declerck P, Simoens S. A European perspective on the market accessibility of biosimilars. Biosimilars. 2012 Nov;33.
10.  Exclusivity Strategies and Opportunities in view of the Biologics Price Competition and Innovation AcVt https://www.jstor.org/stable/26661205
11. Simoens S. Pricing and reimbursement of orphan drugs: The need for more transparency. Vol. 6, Orphanet Journal of Rare Diseases. 2011.
12. Kimball J, Ragavan S, Vegas S. Texas A&M Law Scholarship Texas A&M Law Scholarship Reconsidering the Rationale for the Duration of Data Exclusivity Reconsidering the Rationale for the Duration of Data Exclusivity Recommended Citation Recommended Citation [Internet]. Available from: https://scholarship.law.tamu.edu/facscholar/1399
13. Gherghescu I, Delgado-Charro MB. The biosimilar landscape: An overview of regulatory approvals by the EMA and FDA. Pharmaceutics. 2021 Jan 1;13(1):1–16.
14. Chandana N, Madhavi BLR, Mutta SK, Pulparambil S. A Techno-Legal Study on Current IPR Scenario for Commercialization of Biosimilars in the USA. Journal of Intellectual Property Rights. 2025 May 1;30(3):349–60.
15. Ankit T, Shrikalp D, Maitreyi Z, Praveen Kumar J, Kiran K, Pathak T v. Trivedi Ankit et al / Biosimilar Approval in Europe with Registration Pathways eISSN 1303-5150. NeuroQuantology [Internet]. 2022;20(8):121–9. Available from: www.neuroquantology.com